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ABSTRACT
Signal transducer and activator of transcription
STAT5 is essential for the regulation of prolifera-
tion and survival genes. Its activity is tightly reg-
ulated through cytokine signaling and is often up-
regulated in cancer. We showed previously that the
deacetylase inhibitor trichostatin A (TSA) inhibits
STAT5-mediated transcription by preventing recruit-
ment of the transcriptional machinery at a step fol-
lowing STAT5 binding to DNA. The mechanism and
factors involved in this inhibition remain unknown.
We now show that deacetylase inhibitors do not tar-
get STAT5 acetylation, as we initially hypothesized.
Instead, they induce a rapid increase in global his-
tone acetylation apparently resulting in the delocal-
ization of the bromodomain and extra-terminal (BET)
protein Brd2 and of the Brd2-associated factor TBP to
hyperacetylated chromatin. Treatment with the BET
inhibitor (+)-JQ1 inhibited expression of STAT5 tar-
get genes, supporting a role of BET proteins in the
regulation of STAT5 activity. Accordingly, chromatin
immunoprecipitation demonstrated that Brd2 is as-
sociated with the transcriptionally active STAT5 tar-
get gene Cis and is displaced upon TSA treatment.
Our data therefore indicate that Brd2 is required for
the proper recruitment of the transcriptional machin-
ery at STAT5 target genes and that deacetylase in-
hibitors suppress STAT5-mediated transcription by
interfering with Brd2 function.
INTRODUCTION
Signal transducer and activator of transcription STAT5 is
an essential regulator of cell differentiation, proliferation
and survival (1–3). Following stimulation with specific cy-
tokines, growth factors and hormones, the latent transcrip-
tion factor is phosphorylated by receptor-associated JAK
tyrosine kinases. STAT5 phosphorylation allows its dimer-
ization and translocation into the nucleus where it binds to
conserved recognition sites usually present in the proximal
promoters of STAT5 target genes, resulting in their tran-
scriptional activation (3–5). In normal cells, STAT5 activity
is tightly controlled via attenuation mechanisms including
dephosphorylation by SHP-1 phosphatase and a negative
feedback loop by CIS/SOCS family proteins (6,7). STAT5
activity is further regulated by post-translational modifi-
cations (acetylation, SUMOylation) (2,8–11) and by pro-
tein interactions with itself (tetramerization), transcription
factors, transcriptional coactivators and corepressors, and
with chromatin modifying enzymes (2,12–18). STAT5 ac-
tivity is frequently deregulated in cancer cells, which typi-
cally exhibit constitutively phosphorylated STAT5 due to
the aberrant activity of oncogenic kinases or as a result of
point mutations in STAT5 proteins (19–26). STAT5 con-
stitutive activation results in increased cell proliferation
and reduced cell apoptosis, and is as such an important
player in cancer initiation and progression (3,6,27–30). The
STAT5 pathway is therefore an acknowledged target for
cancer prevention and therapy (31–33). A number of in-
hibitors of the STAT5 pathway have been described, includ-
ing tyrosine kinase inhibitors targeting JAK family mem-
bers and small-molecule inhibitors targeting STAT5 phos-
phorylation or DNA binding activity (34–39). Inhibitors
targeting STAT5 transcriptional activity, at a step subse-
quent to its binding to DNA, have been described. They in-
clude deacetylase inhibitors such as trichostatin A (TSA),
suberoylanilide hydroxamic acid (SAHA) and sodium bu-
tyrate (NaB), initially described by our group, and more
recently the bromodomain inhibitor (+)-JQ1 and the nat-
ural compound sulforaphane (40–43). The mechanism of
inhibition of STAT5 activity by these inhibitors remains
unknown. Therapies combining tyrosine kinase inhibitors
and either deacetylase or bromodomain inhibitors, as well
as therapies combining deacetylase and bromodomain in-
hibitors proved to be more effective in the treatment of can-
cers with constitutive active STAT5 (42,44–49). A number
of deacetylase inhibitors are either approved or currently
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being evaluated for the treatment of various types of cancers
(50). Understanding the mode of action of these inhibitors
is thus not only fundamental for a better characterization
of their activity and specificity but will also contribute to a
better understanding of the mechanism of transcriptional
regulation by STAT5 in normal and cancer cells.
We showed before that the deacetylase inhibitors TSA,
SAHA and NaB inhibit cytokine-induced STAT5 tran-
scriptional activity by preventing recruitment of compo-
nents of the transcriptional machinery (TBP, RNA poly-
merase II) without affecting STAT5 binding to DNA (40).
Analysis of histone H3 and H4 acetylation revealed mi-
nor changes upon TSA treatment along the STAT5 target
gene Cis, as opposed to the control gene c-Fos (41). Be-
side, histone acetylation levels remained particularly low
in the vicinity of the STAT5 binding sites within the Cis
promoter, regardless of interleukin-3 (IL-3) stimulation or
TSA treatment (41). Therefore, our previous data suggested
that deacetylase inhibitors are unlikely to modulate his-
tone acetylation locally and rather block STAT5 activity
by altering properties of the DNA-bound STAT5 protein.
The present study aimed at identifying the molecular mech-
anism of inhibition of STAT5 activity by deacetylase in-
hibitors. STAT5 and other STAT proteins are known to be
acetylated on specific lysines locatedwithin their C-terminal
transactivation domain, DNA binding domain and/or N-
terminal domain (9,10,51–56). The effect of acetylation and
deacetylation on STAT activity varies with the respective
STAT protein. The existence of contradictory reports also
suggest complex spatio-temporal regulatory mechanisms
that might also depend on the cytokine-activated recep-
tors involved and the cell type investigated (9,11,13,53–
55,57–61). STAT1 acetylation on K410 and K413 within
its DNA binding domain inhibits its phosphorylation and
thus its transcriptional activity, in agreement with the re-
quirement of a deacetylase (HDAC) activity for STAT1 sig-
naling (51,58,62). By contrast STAT2 acetylation on K390
(DNA binding domain) is required for the transcriptional
activity of the STAT1/STAT2/IRF9 (ISGF3) complex in-
duced by IFN (52). A number of conflicting results have
been reported regarding the identity of acetylated lysine(s)
within STAT3 and their implication in regulating STAT3
activity. STAT3 acetylation in the cytosol on a single ly-
sine (K685) within the C-terminal SH2 domain did not in-
fluence STAT3 phosphorylation and nuclear translocation
but its dimerization, thus eventually modulating its DNA
binding and transcriptional activities (53,60). By contrast,
Nie et al. showed that acetylation of K685 together with
K679, K707 and K709 is required for STAT3 phosphoryla-
tion and downstream activity (54). This group also showed
that acetylation of N-terminal lysines K49 and K87 does
not play a role in STAT3 activity, which contradicts an-
other report proposing that acetylation at K49 and K87
takes place at a step following STAT3 phosphorylation, nu-
clear translocation and binding to DNA, to allow recruit-
ment and stabilization of p300 and RNA polymerase II,
and thus transcription (55,61). Cytosolic STAT5B acetyla-
tion in response to prolactin at K359 (DNA binding do-
main) andK694 (K689 in STAT5A) and to a lesser extent at
K701 (K696 in STAT5A), both within the C-terminal SH2
domain, did not influence STAT5 phosphorylation but its
dimerization, thus affecting its activity (10). STAT5A acety-
lation at K696, but not at K700, was also reported inde-
pendently (8,56). Interestingly, STAT5 is also SUMOylated
at the same K696 residue. Mutating K696 to arginine par-
tially affected growth hormone (GH)-induced STAT5 activ-
ity in a luciferase reporter assay in mouse embryonic fibrob-
lasts (8), suggesting that acetylation and/or SUMOylation
at K696 might play a role in the regulation of STAT5 activ-
ity.
Existing data thus suggest a possible role of STAT5 acety-
lation at K359, K689 and/or K696 independent of STAT5
phosphorylation (8–11,56,57). We then hypothesized that
the observed inhibitory effect of deacetylase inhibitors on
STAT5 transcriptional activity might involve acetylation
of STAT5, possibly resulting in the disruption of protein–
protein interaction(s) between STAT5 and essential compo-
nents of the transcriptional machinery. Therefore our study
initially aimed at (i) identifying essential lysine residues
within STAT5 that are potentially acetylated upon treat-
ment with deacetylase inhibitors such as TSA, (ii) corre-
lating STAT5 acetylation with a possible alteration in the
composition of STAT5-containing complexes upon TSA
treatment and (iii) identifying among HDAC1–11 (63,64)
the deacetylase(s) responsible for this effect. We found that
mutating multiple lysine residues within constitutively ac-
tive STAT5A-1*6 did not affect its transcriptional activity
in Ba/F3 cells. Besides, TSA treatment did not affect the
gel filtration profile of STAT5-containing complexes. These
observations strongly argued against a direct inhibition of
STAT5 activity through alteration of STAT5 acetylation.
Interestingly, the ability of the deacetylase inhibitors TSA,
valproic acid (VPA) and apicidin to inhibit STAT5 activity
correlated with a rapid and strong increase in global his-
tone acetylation. By contrast, neither STAT5 activity nor
global histone acetylation was affected by the deacetylase
inhibitors MGCD0103 andMS-275. The global increase in
histone acetylation induced by TSA treatment was associ-
atedwith local changes in histone acetylation and a decrease
in histone occupancy at several gene loci, likely reflecting
nucleosome instability provoked by increased acetylation.
We therefore investigated whether changes in chromatin
structure might interfere with the function of chromatin-
associated factors, in particular of those interacting with
acetylated histones. We found that upon treatment with
TSA, VPA and apicidin––but not with MGCD0103 and
MS-275––the bromodomain and extra-terminal (BET) nu-
clear protein Brd2, and to a lesser extent the TATA-box
binding protein TBP, were rapidly depleted from the solu-
ble nuclear fraction but not from the insoluble chromatin
fraction. This finding suggests a rapid delocalization of
Brd2 and of the Brd2-associated factor TBP to hyperacety-
lated chromatin. Further experiments using the bromod-
omain inhibitor (+)-JQ1 and chromatin immunoprecipita-
tion (ChIP) assays using Brd2 antibodies further confirmed
a role of Brd2 in regulating STAT5 activity. Altogether, our
data demonstrate, to our knowledge for the first time, that
deacetylase inhibitors block STAT5 transcriptional activ-
ity by interfering with the function of the BET family pro-
tein Brd2, very likely preventing it from recruiting and sta-
bilizing the transcriptional machinery. Our findings repre-
sent a major step not only in understanding the mechanism
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of transcriptional regulation by the oncoprotein STAT5 but
also in characterizing the mode of action and specificity of
deacetylase inhibitors.
MATERIALS AND METHODS
Chemicals
Dimethyl sulfoxide (DMSO), TSA, MG132 and in-
sulin were purchased from SIGMA (D-2650, T-8552, C-
2211 and I-9278, respectively). (+)-JQ1 (BPS Bioscience
#27401)––hereafter abbreviated to JQ1––was purchased
from BIOMOL GmbH. VPA, apicidin and MS-275 were
purchased from Enzo Life Sciences (ALX-550–304, BML-
GR340 and ALX-270–378, respectively). MGCD0103 (Sel-
leck S1122) was purchased from Absource Diagnostics
GmbH. With the exception of VPA, which was dissolved
at 300 mM in H2O, compounds were dissolved in DMSO
at a final concentration of 1 mM (TSA), 10 mM (Apicidin),
40 mM (MGCD0103), 25 mM (MS-275), 5 mM (JQ1) and
10 mM (MG132). DMSO was used as vehicle control. Its
final concentration was adjusted in all conditions, unless in-
dicated otherwise, and never exceeded 0.12%.
Antibodies
Antibodies used for western blot and ChIP were pSTAT5
(Cell Signaling Technology 9351), STAT5A (Santa Cruz
Biotechnology sc-1081), STAT5B (Santa Cruz Biotechnol-
ogy sc-1656), STAT5A+B (Santa Cruz Biotechnology sc-
835), RNA polymerase II (Santa Cruz Biotechnology sc-
899 and sc-900), TBP (Santa Cruz Biotechnology sc-273),
histoneH3 (Abcamab1791), acetylated histoneH3 (Ac-H3;
Millipore 06–599), acetylated histoneH4 (Ac-H4;Millipore
06–866), -tubulin (Santa Cruz Biotechnology sc-32293),
HDAC1 (Millipore 05–100), HDAC2 (Invitrogen 51–5100),
HDAC3 (Cell Signaling Technology 2632), FLAG (M2,
SIGMA F-1804), Brd2 (Bethyl A302–583A) and IgG from
rabbit serum (SIGMA I-5006; isotype control for ChIP).
Secondary antibodies for western blot were anti-Rabbit
IgG-Peroxidase (SIGMA A-0545) and anti-Mouse IgG-
Peroxidase (SIGMA A-8924).
Cell lines and drug treatments
All cell lines were cultivated at 37◦C under 5% CO2 in a hu-
midified incubator. The IL-3-dependent mouse pro-B cell
line Ba/F3 (a kind gift from Jacqueline Marvel, IFR 128
BioSciences Gerland-Lyon Sud, France) (65) was grown
in RPMI 1640 (PAN-Biotech P04–16500) supplemented
with 10% heat-inactivated fetal calf serum (FCS; PAN-
Biotech), 1% penicillin/streptomycin (PAN-Biotech) and
2 ng/ml rmIL-3 (ImmunoTools). The IL-3-independent
Ba/F3–1*6 cell line (clone F7) stably expressing the con-
stitutively active (FLAG-tagged) mouse STAT5A-1*6 mu-
tant (66) has been recently described (36) and was grown in
RPMI 1640 supplemented with 10% heat-inactivated FCS,
1% penicillin/streptomycin and 600 g/ml G418 (SIGMA
A-1720). The Ba/F3-tet-on-1*6 cell line was generated by
stably transfecting Ba/F3 cells with the pTet-On Advanced
vector (Clontech) expressing the rtTA-Advanced transac-
tivator under neomycin (G418) selection. A clone highly
expressing the transactivator was selected and stably co-
transfected with a tetracycline-responsive vector condition-
ally expressing FLAG-tagged mouse STAT5A-1*6 (pTRE-
Tight-BI-AcGFP1-mSTAT5A-1*6-FLAG) and pTK-Hyg
(Clontech) to confer hygromycin B resistance. Upon hy-
gromycin B selection, clones highly expressing mSTAT5A-
1*6-FLAG in the presence of 1 g/ml of the tetra-
cycline analog doxycycline (SIGMA D-9891) were se-
lected and further characterized (paper in preparation).
Ba/F3-tet-on-1*6 clone D4.1 was chosen for our study.
Non-induced Ba/F3-tet-on-1*6 cells were grown in RPMI
1640 supplemented with 10% heat-inactivated FCS, 1%
penicillin/streptomycin, 600 g/ml G418, 800 g/ml hy-
gromycin B (PAN-Biotech) and 2 ng/ml rmIL-3. Expres-
sion of mSTAT5A-1*6-FLAG was induced by growing the
cells 24 h in RPMI 1640 supplemented with 10% heat-
inactivated FCS, 1% penicillin/streptomycin and 1 g/ml
doxycycline.
For cytokine stimulation of Ba/F3 cells, cells were
washed twice in RPMI 1640 and rested in RPMI 1640/10%
FCS/1% penicillin-streptomycin for 6–12 h before addition
of 2–5 ng/ml IL-3 for 30–120 min, as indicated.
For inhibitor treatment of Ba/F3 cells, unless indicated
otherwise, rested cells were pre-treated 30 min with the re-
spective compound or with DMSO (vehicle) prior to IL-3
stimulation. Ba/F3–1*6 cells were treated with inhibitors or
vehicle for 5–240 min, as indicated.
Plasmid transfection by electroporation
Lysine to glutamine (K>Q) and lysine to arginine (K>R)
point mutations were introduced within mouse STAT5A-
1*6 (K84, K359, K384, K675, K681, K689, K696, K700)
of pcDNA3-mSTAT5A-1*6-FLAG vector (36) by fol-
lowing the QuikChange site-directed mutagenesis proto-
col (oligonucleotides used shown in Supplementary Ta-
ble S1). Multiple mutants (the so-called 2xQ/R for the
K696/K700 double K>Q or K>R mutants, 3xQ/R for
the K689/K696/K700 triple K>Q or K>R mutants and
5xQ/R for the K675/K681/K689/K696/K700 quintuple
K>Q or K>R mutants) were also generated. As a positive
control for inactivatingmutation, the tyrosine residue at po-
sition 694 of mSTAT5A-1*6, which is essential for its phos-
phorylation and activity (66), was mutated to phenylala-
nine (Y694F). All mutations were confirmed by sequencing.
Plasmid pcDNA3-mSTAT5A-FLAG, expressing wild-type
mouse STAT5A, was used as a negative control for STAT5
activity in IL-3-free medium. Empty pcDNA3 vector (In-
vitrogen) was also tested in parallel.
Expression plasmids were prepared with the Plasmid
Pure Midi Kit (Qiagen) and transfected into Ba/F3 cells
by electroporation using the Gene Pulser Xcell Electropo-
ration System with CE Module (Bio-Rad). Briefly, 4 × 106
cells were mixed with 8 g plasmid DNA in 800 l RPMI
1640, transferred into a 0.4 cm gap cuvette (VWR) and
electroporated by delivering one exponential decay pulse
of 320 V and 950 F. Transfected cells were returned to
RPMI 1640/10% FCS/1% penicillin–streptomycin for 10 h
in the absence of IL-3, and harvested for gene expression
and western blot analyses, as described below.
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siRNA transfection by electroporation
HDAC-specific and ScI control siRNAs (Supplementary
Table S1) were transfected into Ba/F3 and Ba/F3–1*6 cells
by electroporation using either the Bio-Rad Gene Pulser II
with RF Module (Supplementary Figure S4 A–D) as pre-
viously described (41), or the Bio-Rad Gene Pulser Xcell
with CE Module (Supplementary Figure S4 E–G) as fol-
lows. Ba/F3–1*6 cells were subjected to two rounds of elec-
troporation (at t = 0 and at 24 h) and harvested at 48–72
h for gene expression and western blot analyses. Per trans-
fection, PBS-washed 1 × 106 cells were resuspended in 100
l Gene Pulser Electroporation Buffer (Bio-Rad) contain-
ing 0.5 to 1 M siRNA duplexes, transferred to a 0.1 cm
gap cuvette (VWR) and electroporated through delivery of
two square wave pulses of 95V, 5 ms duration and 0.1 s in-
terval. Transfected cells were returned to RPMI 1640 sup-
plemented with 10% FCS and 1% penicillin/streptomycin.
Multiple siRNA transfections were performed using equiv-
alent amounts of each siRNA up to the final siRNA con-
centration indicated.
Gene expression analysis by quantitative RT-PCR
Following inhibitor and cytokine treatments, cells were har-
vested, lysed in the iScript RT-qPCR sample preparation
reagent (170–8899, Bio-Rad Laboratories) at a concentra-
tion of 4 × 105 cells/ml and 1 l was used for cDNA syn-
thesis using the iScript cDNA Synthesis kit (170–8891, Bio-
Rad Laboratories), following the manufacturer’s instruc-
tions. Quantitative PCR was performed on a RotorGene Q
(Qiagen) using a 2-step PCR program (95◦C 15 s, 60◦C 60
s; 40 cycles). Twenty microliter quantitative PCR reactions
were performed using 0.4 l cDNA template and a self-
made master-mix containing SYBR Green I and HotStar-
Taq (Qiagen). Mouse-specific quantitative PCR primers
used are listed in Supplementary Table S1. Data were nor-
malized to mouse S9 or 36b4 ribosomal mRNAs and ex-
pressed as relative mRNA levels, like previously reported
(4,36,40,41,43,67). Data are mean ± SD of the quantitative
PCR performed in either duplicate or triplicate and are rep-
resentative of at least two independent experiments.
Quantitative chromatin immunoprecipitation (ChIP) assays
ChIP of STAT5, RNA polymerase II, total histone H3,
acetylated histones H3/H4 and Brd2 (Ba/F3 cells) was per-
formed from whole cell extracts as previously described
(36,40,43). Improved Brd2 detection in Ba/F3–1*6 cells by
ChIP was achieved using an alternative protocol of nu-
clei fractionation and chromatin shearing, adapted from
Me´tivier et al. (68) and Okada and Fukagawa (69) re-
spectively, with the following modifications. Formaldehyde-
crosslinked cells (36,40,43) were sequentially lysed follow-
ing Me´tivier’s protocol (68). Nuclei were resuspended in
HDG150 buffer (20mMHEPES pH7.6, 150mMKCl, 10%
glycerol, 0.5 mM DTT, 10 mM NaF, 10 g/ml leupeptin,
10g/ml aprotinin, 0.5 mMphenylmethylsulfonyl fluoride)
and sonicated six times for 20 s on a Branson Sonifier 250
(output 3, 50% duty cycle). Chromatin was further frag-
mented by MNase digest (SIGMA N-3755; reconstituted
in 5 mM Tris pH 6.8, 50 mM NaCl, 50% glycerol) using
0.25 UMNase/106 cells for 60 min at +4◦C in the presence
of 3 mM CaCl2. MNase activity was stopped with 5 mM
EGTA and the sheared nuclear lysate was diluted 5-fold in
immunoprecipitation (IP) buffer (40). After centrifugation
(3000 x g, 10 min at +4◦C), the supernatant was further pre-
cleared against protein A-sepharose andChIP conducted as
previously described (36,40,43), using 3 g of Brd2-specific
antibody or of rabbit IgG as a control.
Co-precipitated genomic DNA was quantified by quan-
titative PCR using primers listed in Supplementary Table
S1. Data are expressed as percentage (%) of input DNA
or––when histone H3 and H4 acetylation was normalized
to histone H3 content––as Ac-H3/H3 and Ac-H4/H3 % of
input DNA ratios. Data are mean ± SD of the quantita-
tive PCR performed in either duplicate or triplicate and are
representative of at least two independent experiments.
Protein analysis
For Brij whole-cell protein lysis, cells were resuspended in
Brij Lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl,
2 mMEDTApH 8.0, 0.875%Brij 97, 0.125%NP40, 10mM
NaF, 1 mM Na3VO4, 10 g/ml leupeptin, 10 g/ml apro-
tinin, 0.5mMphenylmethylsulfonyl fluoride), lysed by incu-
bation 30 min at +4◦C with occasional stirring, and debris
was eliminated by centrifugation for 15 min at 20,000 x g at
+4◦C.
Freeze-thaw whole-cell protein lysis for the analysis of hi-
stone protein level and acetylation was performed as previ-
ously described (43).
For cytosolic and nuclear protein lysis, cells were gen-
tly resuspended in buffer A (10 mM HEPES pH 7.6, 15
mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 10 mM NaF,
10 g/ml leupeptin, 10 g/ml aprotinin, 0.5 mM phenyl-
methylsulfonyl fluoride) containing 0.1–0.2% NP40, cen-
trifuged at 500 x g for 1 min and the supernatant collected
(cytosolic fraction). Nuclei were washed once in buffer A
and lysed by incubation 30 min at +4◦C in buffer C (50 mM
HEPES pH 7.9, 400 mM KCl, 0.1 mM EDTA, 10% glyc-
erol, 10mM NaF, 10 g/ml leupeptin, 10 g/ml aprotinin,
0.5 mM phenylmethylsulfonyl fluoride). Insoluble particles
were eliminated by centrifugation (15min at 20,000 x g) and
the cleared supernatant (nuclear fraction) was collected.
For subfractionation of nuclei into soluble and insolu-
ble fractions, cells were first lysed in buffer A containing
0.1% NP40 (cytosolic extraction), and nuclei washed once
in buffer A, as above. Nuclei were resuspended in Brij Lysis
buffer and incubated for 30min at +4◦Con a rotatingwheel.
After centrifugation at 1000 x g, the supernatant containing
the soluble nuclear proteins was collected. The insoluble nu-
clear pellet was resuspended in the same volume of Brij Ly-
sis buffer, freezed-thawed once and treated with 0.1 mg/ml
DNase I in the presence of 7 mM MgCl2 for 30 minutes
at +4◦C on wheel. One volume of 2x Laemmli buffer con-
taining -mercaptoethanol was added, samples were heated
at 95◦C for 10 minutes while vortexed regularly. Denatured
samples were centrifuged 10 minutes at maximum speed at
room temperature, to eliminate remaining insoluble debris,
and the supernatant correspondingmainly to the chromatin
fraction was collected. It should be noted that a small vis-
cous pellet remained at this last centrifugation step, indicat-
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ing that a certain amount of undigested DNA and possibly
associated proteins were not extracted.
Immunoblotting was performed as recently described
(36).
Gel filtration
For gel filtration chromatography and analysis of STAT5-
containing protein complexes, nuclear lysates from 5 × 107
Ba/F3–1*6 cells treated for 60 min with 200 nM TSA or
0.02% DMSO (vehicle) were prepared in buffer C as de-
scribed above, dialyzed 50 min against GF buffer (25 mM
HEPES pH 7.2, 0.1 M KCl, 0.1 mM EDTA, 5% glycerol,
1 mM DTT, 100 g/ml insulin, 1 mM phenylmethylsul-
fonyl fluoride, 2 mM benzamidine-HCl) and debris was re-
moved by centrifugation. TSA-treated samples were pro-
cessed in buffers containing 20 nM TSA. Sample volume
was adjusted to 600 l and 500 l was loaded on a TSK-
Gel 4000SW column (Tosoh Bioscience) and separated us-
ing A¨KTA FPLC system (GE Healthcare). Thyroglobulin
(669 kDa) and BSA (66 kDa) were used as protein stan-
dards. Proteins were eluted in GF buffer at a flow rate of
0.5 ml/min. Fractions of 500 l volume were collected and
analysed by western blot using antibodies directed against
FLAG tag (recognizing mSTAT5A-1*6-FLAG fusion pro-
tein), STAT5A+B and RNA polymerase II.
RESULTS
STAT5 acetylation at multiple lysines is not essential for its
transcriptional activity in Ba/F3 cells
We showed before that deacetylase inhibitors such as TSA,
SAHA or NaB inhibit STAT5 transcriptional activity by
preventing recruitment of TBP and RNA polymerase II to
the promoter of target genes such as Cis and Osm, at a
step following STAT5 binding toDNA (40). STATproteins,
in particular STAT3 and STAT5, are known to be regu-
lated by acetylation of multiple lysines (8–10,53–56). There-
fore, we investigated whether alteration of STAT5 acety-
lation might explain the observed effect of deacetylase in-
hibitors on STAT5 activity by introducingmutations at spe-
cific lysine residues. To prohibit a possible interference with
STAT5 initial activation (phosphorylation, dimerization,
nuclear translocation, DNA binding) and instead directly
address an effect on STAT5 transcriptional activity, muta-
tions were introduced in the constitutively active STAT5A-
1*6 protein (66). So far, inhibition of STAT5 transcrip-
tional activity by deacetylase inhibitors was only demon-
strated in cells expressing wild-type STAT5 (40,41). There-
fore, we first verified that constitutive activity of STAT5A-
1*6 was equally sensitive to TSA. Upon treatment of IL-3-
independent Ba/F3–1*6 cells with 200 nM TSA, constitu-
tive expression of STAT5 target genes such asCiswas down-
regulated (Figure 1 and data not shown). ChIP assays con-
firmed that RNA polymerase II occupancy at the Cis tran-
scription start site was reduced in a time-dependent man-
ner, in correlation with the transcriptional inhibition, while
STAT5 DNA binding activity remained unaffected (Figure
1). Thus, in line with our reported observations on wild-
type STAT5 in Ba/F3 cells (40,41), transcription mediated
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Figure 1. Constitutive STAT5 activity is inhibited by the deacetylase
inhibitor TSA. Ba/F3–1*6 cells expressing mouse constitutive active
STAT5A-1*6 mutant were treated with 200 nM TSA and harvested at the
indicated times. Expression of the STAT5 target gene Cis was investigated
by quantitative RT-PCR. Binding of STAT5A-1*6 to theCis promoter and
recruitment of RNA polymerase II to the transcription start site of the Cis
gene were monitored by ChIP using primers Cis -188/-104 and -18/+55,
respectively (Supplementary Table S1).
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Figure 2. Structure of the STAT5A-1*6 lysine mutants. (A) Schematic rep-
resentation of mouse wild-type and constitutively active (1*6) STAT5A
proteins. STAT5A-1*6 presents two point mutations (H298R, S710F; *)
responsible for its constitutive activity (66). STAT5A and STAT5A-1*6
cDNAs were subcloned into the pcDNA3 expression vector, in frame
with a C-terminal FLAG tag (not shown), to allow protein detection by
western blot. Specific lysine residues (K84, K359, K384, K675, K681,
K689, K696, K700) were mutated to glutamine (Q) or to arginine (R) by
site-directed mutagenesis. (B) Sequence alignment of the C-terminal SH2
and transactivation domains of mouse (m) and human (h) STAT5A and
STAT5B highlighting conserved lysine residues (*). Lysine residues mu-
tated within mouse STAT5A-1*6 C-terminal domain are specified (K675,
K681,K689,K696,K700).Double (2xQ/R), triple (3xQ/R) and quintuple
(5xQ/R) STAT5A-1*6 lysine mutants were also generated, as indicated.
The essential and constitutively phosphorylated tyrosine Y694 of mouse
STAT5A-1*6 was also mutated into phenylalanine (Y694F), as a control
for STAT5A-1*6 inactivation. N-term., N-terminal domain; DBD, DNA
binding domain; P-Tyr, phospho-tyrosine tail; TAD, transactivation do-
main.
by constitutively active STAT5A-1*6 is also impaired upon
treatment with deacetylase inhibitors, likely through desta-
bilization of the transcriptional machinery.
Lysine to glutamine (K>Q) and lysine to arginine (K>R)
substitutions thatmimic the acetylated or unmodified lysine
respectively (70) were then introduced into STAT5A-1*6.
Lysine residues that were proposed to be critical for the reg-
ulation of STAT5 but also of STAT3 at equivalent positions
(8–10,53–56,60)––namely K84, K359, K384, K675, K681,
K689, K696 and K700––were mutated either individually
or in combination (Figure 2). Transcriptional activity of the
STAT5A-1*6 lysine mutants was assessed upon transfec-
tion in Ba/F3 cells maintained in IL-3-free medium, hence
in conditions where endogenous wild-type STAT5 is inac-
tive. Expression (protein level) and activation (phosphory-
lation) of the respective STAT5A-1*6 mutants were verified
bywestern blot, and their transcriptional activity was evalu-
ated by measuring expression of the STAT5 target gene Cis
by quantitative RT-PCR. Neither single nor multiple lysine
mutations impaired STAT5A-1*6 transcriptional activity
(Figure 3A and B). Of note, STAT5A-1*6 proteins mutated
at lysine 675 (K675Q, K675R as well as 5xQ and 5xR) were
poorly detectable in western blot, likely due to protein insta-
bility, and thus their activity could not be readily assessed.
Nevertheless, these results indicate that acetylation at the
investigated lysines, notably at K359, K689 or K696 previ-
ously reported to be acetylated and important for STAT5
activity (8,10,56), is not required for STAT5A-1*6 activ-
ity in Ba/F3 cells. These experiments therefore indicate
that the impaired STAT5 transcriptional activity induced
by deacetylase inhibitors is unlikely to be due to a change
in STAT5 acetylation, at least at the investigated lysines.
This proposition is further supported by the important find-
ing that the transcriptional activity of STAT5A-1*6 3xQ/R
proteins, mutated simultaneously at K689, K696 andK700,
remained sensitive to TSA (Figure 3C). Of note, the obser-
vation that the STAT5A-1*6 K696Q/R mutants are as ac-
tive as the non-mutated STAT5A-1*6 protein indicates that
not only acetylation but also SUMOylation at K696 is not
required for STAT5A-1*6 transcriptional activity in Ba/F3
cells.
To rule out that the transcriptional activity of the
STAT5A-1*6 lysine mutants was mediated by the co-
translocation of endogenous wild-type STAT5 proteins
to the nucleus––despite the absence of IL-3––we used a
Ba/F3-tet-on cell line which allows the conditional ex-
pression of STAT5A-1*6 in the presence of doxycycline
(Figure 3D). The comparison of the level of endogenous
nuclear STAT5B proteins before and after induction of
STAT5A-1*6 showed no increase of endogenous STAT5 in
the nucleus when STAT5A-1*6 was expressed (Figure 3D).
In addition, no protein interaction between STAT5A-
1*6 and latent endogenous STAT5B could be detected
in co-immunoprecipitation assays (data not shown). It is
therefore unlikely that the transcriptional activity of our
STAT5A-1*6 mutants is mediated by endogenous STAT5
proteins. Overall, our data strongly argue against an impli-
cation of STAT5 acetylation in the mechanism of inhibition
of STAT5-induced transcription by deacetylase inhibitors.
On the other hand, we cannot fully exclude that an essential
not-yet-described lysine within STAT5 may account for the
observed effect.
Our initial hypothesis assumed that alteration of STAT5
acetylation might disrupt protein–protein interactions be-
tween STAT5 and the transcriptional machinery. We there-
fore compared the profiles of STAT5- andRNApolymerase
II-containing complexes in nuclear extracts from Ba/F3–
1*6 cells treated for 1 h with 200 nM TSA or DMSO (ve-
hicle), which were produced by gel filtration chromatogra-
phy (Supplementary Figure S1). No apparent alterations in
the elution profiles were noticed upon treatment with the
deacetylase inhibitor.
Taken together, these experiments indicate that TSA-
mediated inhibition of STAT5 target gene expression occurs
independently of STAT5 acetylation and is not associated
with an apparent disruption of STAT5-containing protein
complexes.
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Figure 3. Lysine acetylation is not required for STAT5A-1*6 transcriptional activity in Ba/F3 cells. (A–C) Ba/F3 cells were transfected with empty
pcDNA3 (-) or pcDNA3-based plasmids expressing wild-type mSTAT5A, constitutively active mSTAT5A-1*6 or mSTAT5A-1*6 mutants (K>Q, K>R
and Y694F), as indicated. Transfected cells were maintained for 10 h in IL-3-free medium to prevent activation of endogenous STAT5. In (C), transfected
cells were treated with 200 nM TSA or 0.02% DMSO (vehicle) for the last 90 min before harvest. Transgene expression and phosphorylation of STAT5
proteins were verified by western blot analysis of Brij whole-cell lysates using FLAG- and pSTAT5-specific antibodies, respectively. -Tubulin was used as
a loading control. Expression of the STAT5 target gene Cis was investigated by quantitative RT-PCR, as before. Of note, data not shown suggest that the
weaker pSTAT5 signal consistently detected for the 3xQ mutant is likely due to epitope masking, probably as a result of multiple adjacent K>Qmutations
surrounding the phospho-tyrosine residue. (D) Ba/F3-tet-on-1*6 cells were grown for 22 h in the absence or presence of 1 g/ml doxycycline (Dox)
to induce mSTAT5A-1*6 expression. Cells were kept in IL-3-containing medium for the first 12 h, washed twice in RPMI 1640 and further cultivated
in IL-3-deprived medium for 10 h (±Dox, -IL-3) until harvest to inactivate endogenous STAT5 activity. As a positive control for endogenous STAT5
activity, non-induced cells were maintained in IL-3-containing medium (-Dox, +IL-3) for the duration of the experiment (22 h). Cytosolic and nuclear
protein lysates were analysed by western blot to monitor endogenous nuclear STAT5B protein level (STAT5B) before and after induction of STAT5A-1*6
(FLAG). -Tubulin and HDAC1 served as cytosolic and nuclear markers, respectively, to verify the quality of cell fractionation.
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STAT5 target gene expression is differentially affected by
class I-selective deacetylase inhibitors
We next aimed to identify which of the 11 deacetylases
(HDAC1–11) described so far (63,64) might be implicated
in the effect mediated by deacetylase inhibitors. First, class
I-selective deacetylase inhibitors were tested for their ability
to inhibit STAT5 target gene expression. Then, the conse-
quences of siRNA-mediated knockdownof putativeHDAC
candidates on STAT5 target gene expression were inves-
tigated. Ba/F3 cells were pre-treated 30 minutes with in-
creasing amounts of VPA, apicidin, MGCD0103 and MS-
275 before stimulation with IL-3 for 1 h. Expression of
STAT5 target (Cis, c-Myc, Osm) and control (c-Fos, 36b4)
genes (4,36,40,41,43) was measured by quantitative RT-
PCR (Figure 4 and Supplementary Figure S2). Similarly
to TSA (Figure 4 and (40)), VPA and apicidin specifically
inhibited STAT5-mediated transcription of Cis, c-Myc and
Osm, while upregulating expression of the control gene c-
Fos. By contrast, treatment with MGCD0103 and MS-275
had either marginal or no effects on the expression of all
genes investigated. Expression of the Housekeeping gene
36b4 remained unaffected in all conditions (Figure 4). The
deacetylase inhibitor concentrations used were in the range
of the IC50 reported in the literature for the in vitro inhi-
bition of recombinant human HDACs (Supplementary Ta-
ble S2), and therefore were only indicative of their potential
activity in cell culture. Nevertheless, the comparison of the
concentration of deacetylase inhibitor necessary to inhibit
STAT5 activity in Ba/F3 cells to the reported IC50 (Supple-
mentary Table S2) supported the possibility that HDAC5,
7, 9 and 10might represent potential candidate deacetylases
for the regulation of STAT5 activity. Before knocking down
the expression ofHDAC genes, expression levels of individ-
ual HDACs in Ba/F3 cells were characterized by quantita-
tive RT-PCR. While HDAC9 and HDAC11 mRNA levels
were below the limit of detection, HDAC1–8 and HDAC10
were expressed at various levels in Ba/F3 cells, regardless
of the presence of IL-3 (Supplementary Figure S3). Thus,
the potential candidate HDAC9 is unlikely to be involved
in TSA-mediated inhibition of STAT5 activity. Together,
this preliminary screen suggested a possible implication of
HDAC5, HDAC7 and/or HDAC10.
siRNA-mediated knockdown assays were then con-
ducted to identify the HDAC(s) implicated in the regu-
lation of STAT5-mediated transcription. Multiple experi-
ments were conducted both in IL-3-stimulated Ba/F3 cells
and in Ba/F3–1*6 cells, targeting not only the candidate
HDACs mentioned above but also all 11 HDACs, individ-
ually as well as in a number of combinations (Supplemen-
tary Figure S4). The knockdown efficiency was verified at
the RNA levels and, when western-blot-grade antibodies
were available, at the protein level. Unexpectedly, none of
the HDAC knockdowns performed had an effect on the ex-
pression of STAT5 target genes (Supplementary Figure S4).
The observation that transfection of HDAC-specific siR-
NAs did not mimic the inhibitory effect of deacetylase in-
hibitors suggests that the knockdown efficiency was not suf-
ficient or/and that several HDACs are functionally redun-
dant. In support to these propositions, the level of histone
acetylation in cells transfected with HDAC1-, 2-, 3- or 5-
specific siRNAswas onlymarginally increased (Supplemen-
tary Figure S4F). On the other hand, transfection ofHDAC
expression plasmids had no effect on STAT5 target gene ex-
pression and histone acetylation (data not shown). In sum-
mary, the initial screen using class I-selective deacetylase in-
hibitors suggested a subset of HDACs as candidates pos-
sibly involved in STAT5 target gene expression. However,
neither downregulation nor overexpression of the respective
HDACs allowed a definite identification. Consequently, we
decided to find alternative explanations for the observation
that deacetylase inhibitors differentially affect STAT5 tar-
get gene expression.
Histone acetylation is strongly and rapidly increased upon
treatment with deacetylase inhibitors that inhibit STAT5-
mediated transcription
Since STAT5 acetylation did not appear to account for the
observed inhibition of STAT5-mediated transcription by
the deacetylase inhibitors TSA, VPA and apicidin, we re-
assessed the possibility that changes in histone acetylation
might be instead involved. We showed before that histone
H3 and H4 acetylation along the Cis gene was at its low-
est level in the vicinity of the STAT5 binding sites, which
are located in the proximal promoter (41). Histone acety-
lation remained low at the STAT5 binding sites following
both IL-3 stimulation and––most importantly––treatment
with TSA (41). Moreover, TSA did not markedly alter the
level of histone H3 and H4 acetylation at the promoter and
within the open reading frame (ORF) of the Cis gene dur-
ing IL-3 stimulation (41). Consequently, we had proposed
that inhibition of STAT5 target gene expression by deacety-
lase inhibitors do not incriminate local alterations in his-
tone acetylation (40,41). However, it remains possible that
major alterations in chromatin structure at other loci might
have an indirect impact on the regulation of STAT5 target
genes. One drawback of our initial studies was that ChIP re-
sults from the analysis of histone acetylation at theCis gene
locus could not be corrected for changes in histone occu-
pancy, since ChIP-grade and validated histone H3 antibod-
ies were not available at that time. We therefore decided to
reconsider the possibility that altered histone acetylation is
involved in the inhibition of STAT5 target gene transcrip-
tion upon treatment with deacetylase inhibitors.
We first investigated the global effect of deacetylase in-
hibitors on histoneH3 andH4 acetylation. Ba/F3 cells were
treated for 0, 15, 30 and 60 min with the deacetylase in-
hibitors that were either effective (200 nMTSA, 3mMVPA,
500 nM apicidin) or ineffective (1 M MGCD0103, 5 M
MS-275) in inhibiting STAT5 target gene expression. His-
tone H3 and H4 acetylation was evaluated by western blot,
in parallel to total histone H3 as a control (Figure 5). In-
terestingly, treatment with TSA, VPA and apicidin, but not
with MGCD0103 or MS-275, resulted in a strong increase
in histone H3 and H4 acetylation in Ba/F3 cells, in a time-
dependent manner. This effect was rapid, detectable already
after 15 min treatment. The observation that this rapid in-
crease in histone acetylation correlated with the observed
inhibition of STAT5 transactivation properties raises the
possibility that these two events are related. It should be
noted that the absence of effect of MGCD0103 and MS-
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Figure 4. STAT5 activity in Ba/F3 cells is differentially affected by class I-selective deacetylase inhibitors. Rested Ba/F3 cells were pre-treated with the
indicated concentrations of the pan-inhibitor TSA and of the class I-selective deacetylase inhibitors VPA, apicidin, MGCD0103 and MS-275 for 15 min
(TSA) or 30 min (all others), and further stimulated with IL-3 for 60 min, as described in Materials and Methods section. Final DMSO concentration was
adjusted as detailed in legend to Supplementary Figure S2. Expression of STAT5 target (Cis, c-Myc, Osm) and control (c-Fos, 36b4) genes was evaluated
by quantitative RT-PCR as before. Data are expressed as mRNA levels in IL-3-stimulated cells relative to vehicle control. Non-normalized data are shown
in Supplementary Figure S2.
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Figure 5. Histone acetylation is rapidly and specifically increased upon treatment with deacetylase inhibitors that inhibit STAT5 activity. Ba/F3 cells were
treated for 0–60 min with 200 nM TSA, 3 mM VPA, 500 nM apicidin, 1 MMGCD0103 or 5 MMS-275. Freeze-thaw protein lysates were analysed by
western blot using antibodies directed against acetylated histone H3 (Ac-H3), acetylated histone H4 (Ac-H4) and total histone H3 (H3) as loading control.
275 treatment on global histone H3 and H4 acetylation was
likely due to the short duration of treatment applied (up
to 90 min). Indeed, increased histone acetylation induced
by comparable concentrations of MGCD0103 andMS-275
was demonstrated following 24 h of treatment in various cell
lines (71,72). Accordingly, prolonged treatment (10 h) with
MS-275 was associated with both increased histone acetyla-
tion and reducedCis gene induction (SupplementaryFigure
S5).
TSA treatment results in alterations in histone occupancy
and acetylation at various gene loci and differentially affects
RNA polymerase II recruitment
The observed drastic increase in global histone acetylation
might have consequences on chromatin organization. Thus,
ChIP experiments were performed to analyse histone H3
occupancy, histone H3 and H4 acetylation and RNA poly-
merase II recruitment at the STAT5 target genes Cis and
Osm and at the control genes c-Fos and p21 (40) following
treatment with TSA. Both c-Fos and p21 are IL-3 inducible
STAT5-independent genes whose expression is upregulated
upon treatment with deacetylase inhibitors via a local in-
crease in histone acetylation (40,41,73).We first investigated
the possible occurrence of chromatin alterations upon treat-
ment of unstimulated cells with TSA, that is prior to STAT5
activation. Ba/F3 cells were withdrawn from IL-3 as usual
and treated with 200 nM TSA or vehicle for 5, 15, 30 and
60 min. After 30 min TSA pre-treatment, some cells were
also stimulatedwith IL-3 for 30min.HistoneH3 occupancy
around the STAT5 binding sites of Cis and Osm (within
their proximal promoters) and the proximal promoters of c-
Fos and p21, as well as RNA polymerase II association with
the transcription start site (TSS) of the respective genes,
were analysed by ChIP (Figure 6). Interestingly, the amount
of histone H3 detected at the proximal promoters of all four
geneswas reduced uponTSA treatment in a time-dependent
manner. This reduction in histone H3 occupancy might re-
flect a global nucleosome instability following increased hi-
stone acetylation, in agreement with previous reports (74–
79). Of note, a decrease in histone H3 was also detected at
all four proximal promoters upon IL-3 stimulation, suggest-
ing that chromatin remodeling events are also taking place
at these IL-3-induced genes, regardless of STAT5 implica-
tion. In accordance with our previous reports (40,41), IL-
3-induced recruitment of RNA polymerase II at the STAT5
target genes Cis and Osm was abrogated in the presence of
TSA, while it remained unaffected at the control genes c-
Fos and p21 (Figure 6). In addition, an increase in RNA
polymerase II association was detected at all four genes in
unstimulated cells following TSA treatment. This increase is
likely the consequence of an enhanced chromatin accessibil-
ity following increased histone acetylation and nucleosome
loss (74–79). However, RNA polymerase II occupancy in
TSA-treated unstimulated cells remained reproducibly be-
low the level reached in vehicle-treated IL-3-stimulated cells
in the cases of Cis and Osm, by contrast to the control
genes c-Fos and p21 (Figures 6 and 8), suggesting a dis-
tinct mode of recruitment of RNA polymerase II on both
sets of genes. Together, these data demonstrate that, con-
comitantly to a global increase in histone acetylation, TSA
treatment results in similar alterations in chromatin struc-
ture at multiple genes––as evidenced by a local loss in his-
tone H3 occupancy––and differentially affects RNA poly-
merase II recruitment at STAT5 target and control genes.
Our data therefore raise the possibility that recruitment of
RNA polymerase II at STAT5 target genes might require a
chromatin-associated factor(s) which might be lost follow-
ing TSA-induced chromatin reorganization. Noteworthy,
these TSA-induced chromatin changes occur already in un-
stimulated cells, in the absence––hence independently––of
nuclear STAT5.
To better characterize the extent of TSA-induced chro-
matin alterations, we next investigated histone H3 occu-
pancy and histone H3 and H4 acetylation (Ac-H3 and Ac-
H4 respectively) along the Cis gene locus. Ba/F3 cells were
pre-treated 30 min with TSA and further stimulated with
IL-3 for 30 min. Following histone H3, Ac-H3 and Ac-
H4 ChIPs, co-precipitated genomic DNA was analysed by
quantitative PCR using primers covering the -800 to +4000
region (relative to the transcription start site) of theCis gene
(Figure 7 and Supplementary Figure S6). Histone H3 oc-
cupancy was lowest around the STAT5 binding sites and
decreased equally all along the gene locus upon activation
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by IL-3 (Figure 7). Following TSA treatment of unstimu-
lated cells, histone H3 level decreased uniformly along the
gene and remained unchanged upon further stimulation
with IL-3. The fact that the TSA-dependent loss of his-
tone H3 is not further increased upon IL-3 stimulation cor-
relates with the observed inhibition of IL-3-dependent Cis
expression in TSA-treated cells. To better evaluate changes
in histone acetylation following TSA treatment, Ac-H3 and
Ac-H4 signals (Supplementary Figure S6) were normalized
to histone H3 levels (Figure 7). In unstimulated cells, his-
tone H3 and H4 acetylation was low all along the Cis gene
locus. Upon IL-3 stimulation, H3 and H4 acetylation in-
creased in the promoter and ORF––in particular within the
5′ region––but remained low at the STAT5 binding sites, in
agreement with our previous data (41). Histone H3 and es-
pecially histone H4 acetylation was evenly increased along
the Cis gene in unstimulated TSA-treated cells and did not
markedly change following IL-3 stimulation. Ac-H3 and
Ac-H4 pattern in TSA-treated cells (repressed gene) were
distinct from those observed in untreated IL-3-stimulated
cells (activated gene). Our data therefore revealed that (i)
IL-3-induced Cis gene expression correlates with an in-
crease in histone H3 and H4 acetylation and a nucleosome
loss all along the gene locus, and that (ii) TSA treatment re-
sults in a nucleosome loss as well, but in altered histone H3
and H4 acetylation patterns.
Similar changes in histone acetylation and H3 loss were
found not only at the two STAT5 target genes Cis and Osm
but also at the two control genes c-Fos and p21 investi-
gated (Figure 8 and Supplementary Figure S7). Our data
therefore suggest that deacetylase inhibitors such as TSA
induce a rapid and global increase in histone acetylation,
which results in alterations in nucleosome occupancy and
histone acetylation at numerous loci, but has different con-
sequences for the transcription of specific genes. These dif-
ferences point to chromatin-associated factors, in particu-
lar those implicated in the recruitment of the transcriptional
machinery, whose functionmight be affected due to changes
in histone acetylation following TSA treatment.
STAT5-mediated transcription is inhibited by the small-
molecule inhibitor of BET family members (+)-JQ1
One candidate for a chromatin-associated factor inter-
acting with both acetylated histones and the transcrip-
tional machinery (TBP, RNA polymerase II) is Brd2, which
was recently implicated in the regulation of STAT5 ac-
tivity in leukemia cell lines (42). Brd2 belongs to the
BET proteins. The mammalian BET family comprises be-
side Brd2 the Brd3, Brd4 and BrdT proteins. BET fam-
ily proteins are transcriptional regulators containing a
double bromodomain at their amino-terminus and an
extra-terminal protein–protein interaction domain in their
carboxy-terminal region (80). They bind to acetylated his-
tones and regulate transcription through interactions with
transcription factors, multiple chromatin-modifying en-
zymes and components of the transcriptional machinery
such as TBP and RNA polymerase II (80–86). In support
to a role of Brd2 in STAT5-dependent transcriptional regu-
lation in Ba/F3 cells, expression of the STAT5 target genes
Cis, Osm and c-Myc in response to IL-3 was inhibited by
the BET-specific inhibitor (+)-JQ1 (thereafter referred to as
JQ1) in a dose-dependent manner (Figure 9). In contrast,
expression of the control genes c-Fos, p21 and 36b4 was ei-
ther increased or remained unaffected (Figure 9). However,
no cooperative effect between JQ1 and TSA was found in
the presence of sub-optimal concentrations of both com-
pounds (Figure 9), suggesting that both compounds exert
partially overlapping effects.
The BET protein Brd2 is bound to the actively transcribedCis
gene and is delocalized upon TSA treatment, presumably to
hyperacetylated chromatin
Since the above results suggested a possible implication of
Brd2 in STAT5-mediated transcription in Ba/F3 cells, we
investigated whether and how TSA could interfere with
Brd2 function. We first assessed the subcellular localiza-
tion of Brd2 in TSA-treated and untreated Ba/F3 cells
by cell fractionation and western blot analysis (Figure
10). Brd2 was exclusively detected in nuclear extracts of
Ba/F3 cells (Figure 10C), within both the soluble and in-
soluble (i.e. mainly chromatin-associated) nuclear fractions
(Figure 10A and C). Remarkably, upon TSA treatment,
Brd2 protein was depleted from the soluble nuclear frac-
tion while it was still detectable in the insoluble nuclear
fraction (Figure 10A and C). The depletion of Brd2 from
the soluble nuclear fraction was not due to proteasome-
dependent protein degradation since it was not prevented
by pre-treatment with the proteasome inhibitor MG132
(Figure 10A). MG132 activity was verified by measuring
the mRNA levels of hsp70 (Figure 10B), an acknowledged
MG132-induced gene (87). The drop in the level of solu-
ble nuclear Brd2 protein in TSA-treated cells was also not
the consequence of a reduced Brd2 gene expression, since
Brd2 mRNA levels were not affected by TSA (Figure 10B).
These observations suggest that delocalization of nuclear
Brd2 from the soluble to the insoluble chromatin fraction
following TSA treatment could limit its availability to sup-
port STAT5-mediated transcription.
To address that possibility, Brd2 nuclear distribution was
evaluated in Ba/F3 cells treated for 15, 30 and 60 min with
200 nM TSA, as well as for 60 min with the deacetylase
inhibitors impairing (3 mM VPA, 500 nM apicidin) or do
not impairing (1 M MGCD0103, 5 M MS-275) STAT5
target gene expression (Figure 10C). Brd2 loss from the
soluble nuclear fraction was already evident after 15 min
of TSA treatment, and was similarly observed upon treat-
ment with VPA and apicidin, but not with MGCD0103
or MS-275. Strikingly, Brd2 depletion from the soluble
nuclear fraction correlated with the rapid increase in his-
tone H3 and H4 acetylation, which was exclusively detected
within the insoluble chromatin fraction (Figure 10C). Of
note, the soluble cytosolic pool of free histone H3 (88,89)
decreased as the chromatin-bound pool of acetylated hi-
stones increased, suggesting that histones are rapidly in-
corporated into the chromatin upon acetylation induced
by TSA, VPA and apicidin. Given that histone H3 occu-
pancy decreased simultaneously at the various gene loci in-
vestigated, our data suggest a major redistribution of his-
tone H3 within the chromatin upon deacetylase inhibitor
treatment. Brd2 depletion also correlated with a specific de-
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Figure 6. Histone occupancy is reduced at promoters of both STAT5-dependent and -independent genes upon TSA treatment. Ba/F3 cells were withdrawn
from IL-3 for 10 h and treated with 200 nM TSA or 0.02% DMSO (vehicle) for 5, 15, 30 and 60 min. As a control for IL-3 stimulation, Ba/F3 cells were
stimulated with IL-3 for 30 min following a 30 min TSA pre-treatment (hence treated 60 min with TSA). Cells were harvested and processed for ChIP,
as described in Materials and Methods section. ChIP was performed using antibodies directed against total histone H3 or RNA polymerase II (RNA
Pol II). Co-precipitated genomic DNA was analysed by quantitative PCR using primers specific for proximal promoter regions (histone H3 ChIP) or
transcription start sites (RNA Pol II ChIP) of STAT5 target (Cis, Osm) and control (c-Fos, p21) genes. Cis and Osm promoter amplicons overlap their
respective STAT5-responsive elements (Supplementary Table S1).
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Figure 7. Histone occupancy is reduced and histone acetylation is altered all along the Cis gene upon TSA treatment. Rested Ba/F3 cells were pre-treated
30 min with 200 nM TSA or 0.02% DMSO (vehicle) and further stimulated 30 min with IL-3 before being processed for ChIP using antibodies directed
against total histone H3, acetylated histone H3 (Ac-H3) and acetylated histone H4 (Ac-H4). Co-precipitated genomic DNA was analysed by quantitative
PCR using primers specific for the -800 to +4000 Cis gene locus (Supplementary Table S1). Positions of amplicons investigated and of the four STAT5
binding sites arranged in two clusters are indicated along the x axis. Non-normalized Ac-H3 and Ac-H4 ChIP data are shown in Supplementary Figure
S6.
crease of TBP in the soluble nuclear fraction, suggesting
that––concomitantly to Brd2––TBP is also redistributed to
hyperacetylated chromatin. This is in agreement with the
reported interaction between Brd2, acetylated histones and
TBP (82,83,85). STAT5 and RNA polymerase II showed
no apparent depletion from the soluble nuclear fraction
upon deacetylase inhibitor treatment (Figure 10C). Over-
all, these experiments indicate that deacetylase inhibitors
such as TSA, VPA and apicidin––but not MGCD0103 or
MS-275––induce a rapid increase in chromatin acetylation
that might result in a massive delocalization of Brd2 and
of Brd2-associated TBP, likely due to Brd2 preferential
binding to hyperacetylated chromatin (82,83,85). Together
with the finding that the BET-specific inhibitor JQ1 inhibits
STAT5 target gene expression in IL-3-stimulated Ba/F3
cells (Figure 9), our data suggest that Brd2 is required for
efficient STAT5-mediated transcription and that its rapid
redistribution following treatment with TSA, VPA or api-
cidin is responsible for the inhibition of STAT5 transcrip-
tional activity.
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Figure 8. Alterations in histone acetylation by TSA at different gene loci differentially affect gene activation. Rested Ba/F3 cells were pre-treated 30 min
with 200 nM TSA or 0.02% DMSO (vehicle) and further stimulated 30 min with IL-3 before being processed for ChIP using antibodies directed against
RNA polymerase II (RNA Pol II), histone H3, acetylated histone H3 (Ac-H3) and acetylated histone H4 (Ac-H4), as before. Co-precipitated genomic
DNAwas analysed by quantitative PCR at STAT5 target (Cis,Osm) and control (c-Fos, p21) genes, using the same primers as in Figure 6. Non-normalized
Ac-H3 and Ac-H4 ChIP data are shown in Supplementary Figure S7.
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Figure 9. The inhibitor of BET proteins JQ1 inhibits STAT5 activity. Rested Ba/F3 cells were pre-treated 30 min with the indicated concentrations of
JQ1, TSA or vehicle (0.02% DMSO in all conditions) and further stimulated 60 min with IL-3. Expression of STAT5 target (Cis, c-Myc,Osm) and control
(c-Fos, p21, 36b4) genes was evaluated by quantitative RT-PCR, as before.
This model predicts that Brd2 is associated with actively
transcribed STAT5 target genes and that this association is
lost upon TSA (or JQ1) treatment. To validate this model,
Brd2 ChIP assays were conducted in unstimulated versus
IL-3-stimulated Ba/F3 cells as well as in Ba/F3–1*6 cells
treated with 200 nM TSA, 1 M JQ1 or DMSO (vehicle).
Brd2 association with the Cis gene locus was investigated
using primers covering the -800/+4000 region, as before
(Figure 11A and B). Upon IL-3 stimulation of Ba/F3 cells,
Brd2 protein was recruited to the transcription start site of
the Cis gene (Figure 11A), supporting the idea that bind-
ing of Brd2 is STAT5-dependent. Similarly, in untreated
Ba/F3–1*6 cells, Brd2 protein was bound at the transcrip-
tion start site and 5′ region of the open reading frame of the
transcriptionally active Cis gene. As predicted, Brd2 asso-
ciation with the Cis gene was strongly reduced upon treat-
ment with either TSA or JQ1 (Figure 11B and C). By con-
trast, Brd2 protein level detected at the transcription start
site of the control genes c-Fos and p21 was low and re-
mained unaffected by TSA or JQ1 treatment (Figure 11C).
Noticeably, the level of Brd2 protein detected at the tran-
scription start site of the STAT5 target gene Osm was also
low and was reduced in JQ1––but not in TSA-treated cells.
In summary, we showed that the deacetylase inhibitors
TSA, VPA and apicidin––but not MGCD0103 or MS-
275––inhibit STAT5-mediated transcription in correlation
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Figure 10. The nuclear BET protein Brd2 is rapidly relocalized to the chromatin fraction together with acetylated histones upon treatment with deacetylase
inhibitors that inhibit STAT5 activity. (A) Ba/F3 cells were treated with 200 nM TSA, 10 M MG132, both (T+MG) or vehicle (0.12% DMSO final in
all conditions). Cells were treated for a total duration of ∼2 h, with a 45 min MG132 pre-treatment followed by a 90 min TSA treatment. Soluble and
insoluble nuclear fractions were analysed by western blot using antibodies against Brd2 and the nuclear marker HDAC1 as loading control. Similar results
were obtained upon 3 h pre-treatment with 10 M MG132 followed by 90 min incubation with 200 nM TSA (4.5 h treatment in total; not shown). (B)
Ba/F3 cells were rested for 6 h and stimulated with IL-3 for 60 min. Prior to IL-3 stimulation, cells were pre-treated 3.5 h with 10 MMG132, 30 min with
200 nM TSA, both (3hMG132 followed by 30 min TSA) or vehicle (0.12%DMSO final in all conditions). Hence cells were incubated 4.5 h in total with 10
MMG132 and 90 min with 200 nM TSA. Expression of the STAT5 target gene Cis, of the MG132-regulated gene hsp70 and of Brd2 and 36b4 genes as
controls was monitored by quantitative RT-PCR. (C) Ba/F3 cells were treated for the indicated times with 200 nM TSA, 3 mM valproic acid (VPA), 500
nM apicidin (Api.), 1 M MGCD0103 (MGC), 5 M MS-275 (MS), or vehicle (Veh.; 0.02% DMSO final in all conditions). Cytosolic as well as soluble
and insoluble nuclear fractions were analysed by western blot using the indicated antibodies. As before, -tubulin and HDAC1 served as cytosolic and
nuclear markers, respectively, to control cell fractionation.
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Figure 11. Brd2 protein is present at the transcriptionally active Cis locus and is lost following both TSA and JQ1 treatment. (A) Rested Ba/F3 cells were
either kept unstimulated (- IL-3; STAT5 activity off) or stimulated with IL-3 for 30 min (+ IL-3; STAT5 activity turned on). Brd2 ChIP was performed
on sonified whole cell extracts from formaldehyde-cross-linked cells using 3 g of either Brd2-specific antibodies or rabbit IgG (background control).
Co-precipitated genomic DNA was analysed by quantitative PCR using the same Cis primers as in Figure 7. (B, C) Ba/F3–1*6 cells were treated for 60
min with 200 nM TSA, 1 M JQ1 or vehicle (0.02% DMSO). Brd2 ChIP was performed on sonified nuclear extracts from formaldehyde-cross-linked cells
as described in Materials andMethods section using 3 g of either Brd2-specific antibodies or rabbit IgG. Co-precipitated genomic DNA was analysed by
quantitative PCR using the same primers as in panel A (B) or using primers specific for the transcription start site of STAT5 target (Cis, Osm) and control
(c-Fos, p21) genes (Supplementary Table S1) (C).
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with alterations of histone occupancy and acetylation, but
likely independently of STAT5 acetylation. The BET pro-
tein inhibitor JQ1 also inhibits STAT5-mediated transcrip-
tion, suggesting a connection between BET proteins and
STAT5-dependent activation of transcription. Accordingly,
the BET protein Brd2 was bound at the transcriptionally
active Cis gene and was lost upon both JQ1 and TSA treat-
ment. Brd2 loss from the Cis gene following TSA treat-
ment is possibly the consequence of a vast depletion of
Brd2 from the nucleosol due to its preferential interac-
tion with hyperacetylated chromatin, which is induced in
response to TSA treatment. Nucleosolic levels of TBP, a
Brd2 interacting partner, were also reduced upon Brd2 de-
pletion, suggesting that TBP is co-delocalized with Brd2.
It also raises the possibility that one of Brd2 functions is
to assist recruitment and/or stabilization of the transcrip-
tional machinery at STAT5 target genes. Altogether, our
data suggest that the loss of Brd2––and possibly of other
BET proteins––associated with TSA treatment is responsi-
ble for the impaired assembly of the transcriptional machin-
ery and the resulting transcriptional inhibition at STAT5
target genes.
DISCUSSION
We showed before that the deacetylase inhibitors TSA,
SAHA and NaB inhibit STAT5 transcriptional activity at
a step following STAT5 activation and binding to DNA
by preventing recruitment of the transcriptional machinery
(40). The effect of deacetylase inhibitor treatment on local
histone acetylation at the STAT5 target genes was marginal
(40,41) and convinced us to consider the possibility that in-
hibition of STAT5 activity by deacetylase inhibitors targets
STAT5 protein rather than chromatin.
We now show that the effect of deacetylase inhibitors on
STAT5 activity is independent of STAT5 acetylation. Mu-
tation of lysine residues previously shown to be acetylated
within STAT5 not only did not affect expression of endoge-
nous STAT5 target genes in Ba/F3 cells but also did not
suppress the sensitivity to TSA. STAT5 acetylation was pre-
viously shown to take place in the cytosol and play a role
in its dimerization (10). Our results using constitutively ac-
tive STAT5A-1*6 further demonstrate that STAT5 acetyla-
tion is likely required for its initial activation (phosphoryla-
tion, dimerization, nuclear translocation)––a step circum-
vented using constitutively active STAT5A-1*6––but not
for its transcriptional activity. Thismight explain why trans-
activation of a luciferase reporter by a STAT5AK696Rmu-
tant was partially impaired in GH-stimulated mouse em-
bryonic fibroblasts (MEFs) (8), likely as a result of a defec-
tive STAT5 activation rather than a transcriptional defect.
Instead, we found that the deacetylase inhibitors TSA,
VPA and apicidin, but not MGCD0103 and MS-275, in-
duce a rapid increase in global histone H3 and H4 acetyla-
tion, which correlates with their ability to suppress STAT5-
mediated transcription.Our data suggest that the absence of
effect ofMGCD0103 andMS-275 on global histoneH3 and
H4 acetylation is the consequence of a short treatment dura-
tion rather than of compound inactivity. We also found that
the BET protein inhibitor (+)-JQ1 prevents induction of
STAT5 target genes in Ba/F3 cells and that the BET protein
Brd2 is associated with the transcriptionally active Cis gene
in a STAT5-dependent manner, supporting a role of Brd2 in
STAT5-mediated transcription. This is in agreement with
the recent demonstration that BET proteins, in particular
Brd2, regulate STAT5 activity in human leukemia cells (42).
Unexpectedly, we did not observe a synergy between JQ1
and TSA in inhibiting expression of STAT5 target genes
in Ba/F3 cells, which would be anticipated for inhibitors
targeting the same factor. On the other hand, this observa-
tion is in agreement with several recent reports showing that
JQ1 and the pan-deacetylase inhibitor panobinostat (or ty-
rosine kinase inhibitors) synergistically induce apoptosis of
leukemia cells expressing constitutive active STAT5 but not
of normal hematopoietic progenitor cells (42,48,49). A lack
of synergy between JQ1 and TSAmight indicate that the ef-
fect of JQ1 only partially overlaps that of TSA. For instance,
although both JQ1 and TSA alter Brd2 function, JQ1 does
not affect histone acetylation, as opposed to TSA.
The mechanism of STAT5-dependent recruitment of
Brd2 to the Cis gene is still unknown. A direct interaction
between STAT5 and Brd2 could not be demonstrated in co-
immunoprecipitation experiments (data not shown), sug-
gesting that this event takes place at the chromatin level
rather than in solution. The proposition that STAT5 and
Brd2 are unlikely to form a stable complex in solution is also
supported by our observations that TSA treatment has no
effect on (i) the pool of nucleosolic STAT5 detected in west-
ern blot uponBrd2 depletion from the nucleosol, (ii) STAT5
binding to DNA in chromatin immunoprecipitations (this
study and (40,41)) and (iii) the elution profile of STAT5-
containing complexes in gel filtration.
Importantly, we found that Brd2 dissociates from the Cis
gene upon TSA treatment, in correlation with Brd2 deple-
tion from the nucleosol as chromatin becomes hyperacety-
lated. Since Brd2 is known to associate preferentially with
hyperacetylated histones (85), our data suggest that Brd2
is rapidly delocalized to acetylated chromatin upon treat-
ment with deacetylase inhibitors. No increase in Brd2 pro-
tein level was detected in the insoluble chromatin fraction
as nucleosolic Brd2 decreased, which would have been ex-
pected upon Brd2 redistribution. This might be inherent to
the method of protein extraction that we used. We tried but
failed to achieve total protein extraction from the insoluble
nuclear fraction (see Materials and Methods section), and
thus it is possible that part of the chromatin-bound pro-
teins were not loaded on SDS-PAGE. Nevertheless, since
we demonstrated that Brd2 depletion was not due to pro-
tein degradation and since the level of Brd2-associated pro-
teinTBP (82,83) decreased concomitantly, our data strongly
suggest that Brd2 is delocalized, rather than degraded, as
a consequence of its preferential association with hyper-
acetylated histones. Such a mechanism might explain why
we failed to identify the HDAC(s) implicated in STAT5
target gene expression in our siRNA transfection experi-
ments, since global histone acetylation was only marginally
affected in these experiments. Along these lines, the huge in-
crease in histone acetylation observed upon treatment with
TSA, VPA or apicidin suggests that not one but several
HDACs are simultaneously targeted. The use of specific
deacetylase inhibitors might help addressing that point. On
the other hand, the observation that the chemical inhibi-
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tion and physical elimination of HDACs do not have the
same effect on STAT5 target gene expression might reflect
a distinct mode of action of HDACs, possibly independent
of their deacetylase activity, for instance involving HDAC
inhibitor-induced protein complex disruption, in agreement
with previous reports (90–94).
Noticeably, although Osm gene expression was reduced
upon JQ1 treatment, the level of Brd2 protein detected at
the transcription start site was lower than that detected at
the Cis gene and was not reduced upon TSA treatment, in-
dicating that Brd2 is not involved in the regulation of Osm.
This suggests that othermembers of the BET family, such as
Brd3 or Brd4 (80), might also be involved in the regulation
of STAT5 target gene expression.
Brd2 protein interacts with a number of transcription fac-
tors, chromatin-modifying factors and components of the
transcriptional machinery including TBP and RNA poly-
merase II (82,83,86). One can thus anticipate that the abrupt
redistribution of Brd2 interferes with the proper recruit-
ment of transcription regulatory factors to chromatin. Ac-
cordingly, nucleosolic TBP was reduced together with Brd2
depletion upon treatment with TSA, VPA and apicidin. We
propose that TSA-dependent depletion of soluble Brd2 in-
terferes with the proper recruitment and/or stabilization of
the transcriptional machinery. This is also supported by our
observation that TSA treatment of either IL-3-stimulated
Ba/F3 cells or Ba/F3–1*6 cells results in a rapid reduc-
tion of Cis mRNA levels simultaneously to the dissocia-
tion of TBP and RNA polymerase II from the transcription
start site ((40) and Figure 1 respectively). Beside their inter-
action with factors regulating transcription, BET proteins
interact with chromatin remodeling complexes and regu-
late the maintenance of higher-order chromatin structure
(81,83,86). Therefore, it is possible that Brd2 delocaliza-
tion also alters chromatin organization, in agreement with
the nucleosome loss monitored at all the investigated genes
upon TSA treatment.
In summary, we showed that BET proteins including
Brd2 play an important role in the regulation of STAT5 tar-
get gene expression, likely by assisting the recruitment and
stabilization of the transcriptional machinery. We showed,
to our knowledge for the first time, that the function of BET
proteins is altered by deacetylase inhibitors, very likely by
provoking a mislocalization of Brd2 and possibly of other
BET family members to hyperacetylated chromatin (Sup-
plementary Figure S8). Our data thus reveal novel and es-
sential aspects of the mechanism of transcriptional regu-
lation by STAT5 and of its inhibition by deacetylase in-
hibitors, and underscore BET proteins as potential thera-
peutic targets in the treatment of STAT5-associated cancers.
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